Related Experiment Video
Updated: Jun 10, 2026
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Mantle cell lymphoma in relapse: the role of emerging new drugs
Catherine S M Diefenbach1, Owen A O'Connor
1New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA.
Purpose Of Review:
Despite current advances in the therapy for newly diagnosed mantle cell lymphoma (MCL), relapsed MCL continues to have a poor prognosis. Advances in our understanding of the molecular pathogenesis of MCL are yielding many promising novel therapies.
Recent Findings:
This article reviews the unique biology of MCL and describes how our understanding of its cell cycle dysregulation, and impaired apoptotic pathways is yielding many potential therapeutic targets including cyclin D1 and the cell cycle regulatory proteins, inhibitors of mammalian target of rapamycin, the proteasome, and proapoptotic family members. Recent preclinical and clinical data with cdk inhibitors, histone deacetylase inhibitors, the proteasome inhibitor bortezomib, mammalian target of rapamycin inhibitors, and other experimental strategies such as immunotherapy and microRNA are discussed.
Summary:
Understanding these targeted therapies in the context of the biology of MCL, has the potential to develop novel therapeutic platforms for the treatment of relapsed MCL, and will hopefully change the outcome for patients with this challenging clinical condition.
Insights
Novel therapies targeting cell cycle dysregulation and apoptosis show promise for relapsed mantle cell lymphoma (MCL). Understanding MCL biology is key to developing new treatments for this challenging condition.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Relapsed mantle cell lymphoma (MCL) presents a poor prognosis despite current therapeutic advancements.
- Emerging insights into MCL's molecular pathogenesis are paving the way for novel therapeutic strategies.
Purpose of the Study:
- To review the unique biology of MCL.
- To discuss how understanding cell cycle dysregulation and impaired apoptotic pathways in MCL informs potential therapeutic targets.
- To present recent preclinical and clinical data on novel experimental therapies for MCL.
Main Methods:
- Review of existing literature on MCL biology and targeted therapies.
- Analysis of preclinical and clinical data for various inhibitors and experimental strategies.
- Discussion of therapeutic targets including cyclin D1, cell cycle proteins, mTOR, proteasome, and proapoptotic factors.
Main Results:
- MCL biology reveals targets like cyclin D1, cell cycle regulators, mTOR, proteasome, and proapoptotic pathways.
- Investigational agents include CDK inhibitors, HDAC inhibitors, bortezomib, mTOR inhibitors, immunotherapy, and microRNA-based strategies.
- These targeted approaches are being evaluated in preclinical and clinical settings.
Conclusions:
- Targeted therapies informed by MCL biology offer potential for novel treatment platforms.
- Developing these strategies is crucial for improving outcomes in relapsed MCL.
- Further research holds promise for transforming the clinical management of this challenging lymphoma.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...